梅花生物(600873.SH):拉薩梅花不再持有廣生醫藥的股份
格隆匯12月14日丨梅花生物(600873.SH)公佈,截至公吿披露日,協議約定的交割先決條件已滿足,交易各方已就交割確認函達成一致,同時確定廣生醫藥79.51782%股份最終轉讓價款為等值人民幣954,309,261元。拉薩梅花持有的廣生醫藥50.13417%的股份的轉讓價款為人民幣6億元左右。安宏資本SPV已按照協議約定將最終轉讓價款對應的美元金額支付至共管賬户下,廣生醫藥已就上述股權轉讓事項辦理了股東變更的工商登記備案手續,工商變更登記完成後拉薩梅花不再持有廣生醫藥的股份。
工商變更登記完成後,拉薩梅花不再持有廣生醫藥的股份,公司財務報表的合併範圍已發生變化,廣生醫藥不再納入合併報表範圍。此次交易預計增加2021年度投資收益人民幣2億元左右,最終數據以公司經審計的年度財務報吿為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.